Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Phase 2

3(60.0%)

Phase 1

2(40.0%)

5Total

Phase 2(3)

Phase 1(2)

Loading network data...

Showing 5 of 5 trials

Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD)

Role: collaborator

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

Role: collaborator

A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers

Role: lead

A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers

Role: lead

Safety and Effectiveness Study of BCI-540 Versus Placebo in the Treatment of Major Depressive Disorder With Concomitant Anxiety

Role: lead

All 5 trials loaded